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Abstract 
There is an urgent need to develop new and alternative methods to deliver functional 
biomolecules to the brain for diagnosis and treatment of brain diseases. The goal of this study was 
to evaluate the activity of blood-brain barrier (BBB) modulators (i.e., HAV and ADT peptides) to 
deliver functional biomolecules (i.e., galbumin, IRdye800cw-cLABL, and cIBR7) to the brains of 
mice and rats. HAV6, cHAVc3, and ADTC5 peptides but not HAV4 peptide significantly enhanced 
the brain delivery of 65 kDa galbumin compared to control in Balb/c mice as quantified by magnetic 
resonance imaging (MRI). Ten-minute pretreatment with ADTC5 peptide still significantly 
increased brain delivery of galbumin; however, no enhancement was observed after 10-min 
pretreatment with HAV6. There was no enhancement of galbumin deposition following 40-min 
pretreatment with ADTC5 or HAV6, suggesting a short duration of the BBB opening for large 
molecules. ADTC5 peptide also improved the brain delivery of IRdye800cw-cLABL peptide about 
3.5-fold compared to control in Balb/c mice as detected by near infrared fluorescence (NIRF). The 
BBB modulator activity of ADTC5 to deliver cIBR7 peptide was also evaluated in vivo using 
Sprague-Dawley rats. The amount of cIBR7 in the brain was detected by LC-MS/MS. ADTC5 
peptide enhanced the delivery of cIBR7 peptide into rat brain about 4-fold compared to control 
and the intact cIBR7 can be efficiently extracted and detected in rat brain. In conclusion, HAV and 
ADT peptides enhance the brain delivery of functional peptides (e.g., cLABL and cIBR7) and protein 
(e.g., 65 kDa galbumin) in two animal models, and the duration of the BBB opening for a large 
molecule (e.g., galbumin) was short. 
Key words: blood-brain barrier, BBB, brain delivery, cadherin peptides, HAV peptide, ADT peptide, 
paracellular diffusion, tight junction, adherens junction, BBB modulation. 
Introduction 
There is an urgent need to develop new and 
alternative methods to deliver molecules to the brain 
for diagnosis and treatment of brain diseases (i.e., 
Parkinson’s, Alzheimer’s, multiple sclerosis, brain 
tumors) [1, 2]. Furthermore, approaches that can 
safely deliver molecules to the brain can also provide 
opportunities to probe brain functions at the cellular 
and molecular levels using selected imaging and 
cellular signaling molecules. The protective function 








entering the brain; however, under pathological 
conditions, the BBB can also restrict the accumulation 
of drugs to the brain. Numerous invasive methods 
have been developed to directly deliver or sample 
molecules to or from the brain, respectively; these 
methods include (a) brain microdialysis [3], (b) 
intracerebral implantation [4], and (c) intraventricular 
delivery [5]. However, these methods can be 
problematic for patients, and these invasive 
approaches can cause damage in the surrounding 
brain tissues. Alternatively, various non-invasive 
approaches have been developed to improve brain 
delivery of molecules, including the use of (a) 
prodrug technology, (b) efflux pump inhibitors, (c) 
receptor-mediated transport, (d) osmotic agents, and 
(e) BBB modulators; however, in general, the success 
of these methods has been limited [1, 2, 6, 7]. 
One way to deliver drug and diagnostic 
molecules to the brain is via the transcellular 
pathway, allowing the molecule to diffuse through 
the membranes of the BBB endothelial cells. 
Traditionally, changing the physicochemical 
properties of the drug was done to improve its brain 
delivery via the transcellular pathway. However, 
changing the drug structure may alter its biological 
activity. As an alternative, several prodrug methods 
have been developed to transiently change the 
physicochemical properties of the drug, permitting 
greater transcellular BBB penetration [1]. Although 
the physicochemical properties of the drug can be 
changed to improve its membrane partition for 
transcellular passive diffusion, the presence of efflux 
pumps on the BBB can prevent the drug molecule 
from crossing the BBB cell membranes. Inhibitors 
have been designed to block the activity of efflux 
pumps in allowing the drug to cross the BBB [1]. 
Receptor-mediated transcytosis has also been 
explored for improving brain delivery of molecules. 
For example, the high expression of transferrin 
receptors on the luminal side of brain capillary 
endothelial cells has been exploited as a carrier of 
drugs/macromolecules across the BBB, and has 
shown promise in pre-clinical animal models [2, 8]. 
An alternative approach to deliver molecules 
across the BBB is via the paracellular pathway by 
increasing the porosity of the intercellular junctions. 
Under normal conditions, the penetration of 
molecules through this pathway is limited by the 
presence of the tight intercellular junctions. Therefore, 
modulation of these junctions is needed to improve 
paracellular passive diffusion of molecules. One 
successful method for enhancing paraceullar delivery 
across the BBB that has been used in the clinic to 
deliver anticancer drugs to brain tumor patients is 
hyperosmotic agents such as mannitol. In this case, 
administration of osmotic agents is used to produce a 
hypertonic environment within the brain vasculature, 
causing shrinkage of endothelial cells of the BBB and 
allowing opening of the tight junctions for molecules 
to cross via paracellular pathways [9]. The positive 
results from the osmotic method have stimulated 
investigation of other methods to transiently 
modulate the integrity of the BBB to enhance molecule 
delivery via the paracellular pathway. Several 
molecules have been developed to modulate the 
intercellular junctions of the BBB, including 
bradykinin derivatives and inhibitors of cell-cell 
adhesion proteins (i.e., occludins, claudins, cadherins) 
[10-13].  
Our group have designed and utilized cadherin 
peptides called HAV (His-Ala-Val) [14] and ADT 
(Ala-Asp-Thr) [15] peptides derived from the 
extracellular domain-1 (EC1) of E-cadherin (Table 1) 
to modulate the intercellular junctions of the BBB and 
improve paracellular penetration of functional 
biomolecules (i.e., peptides and proteins). Previously, 
HAV and ADT peptides have been shown to enhance 
the in vivo brain delivery of small-to-large marker 
molecules (e.g., 14C-mannitol, gadopentetic acid, and 
25 kDa polyethylene glycols (PEG)) in mice and rats 
[16-20]. However, the utility of HAV and ADT 
peptides in enhancing in vivo brain delivery of 
proteins and peptides has not yet been evaluated. 
Thus, the aim of this work was to evaluate the ability 
of cadherin peptides to enhance brain delivery of 
galbumin, IRdye800cw-cLABL peptide, and 
unlabeled cIBR7 peptide.  
 
Table 1. Peptide Names and Peptide Sequences 
Peptide 
Name 
Sequence Peptide Origin 
HAV6  Ac-SHAVSS-NH
2
  EC1 of E-cadherin 
HAV4  Ac-SHAVAS-NH
2
 Ala5 mutant of HAV6 
cHAVc3  Cyclo(1,6)Ac-CSHAVC-NH
2
 EC1 of E-cadherin 
ADTC5 Cyclo(1,7)Ac-CDTPPVC-NH
2
 EC1 of E-cadherin 
cLABL Cyclo(1,12)PenITDGEATDSGC I-domain of LFA-1 
cIBR7 Cyclo(1,8)CPRGGSVC D1 of ICAM-1 
IS Cyclo(1,8)CPRGGSIC Ile7 mutant of cIBR7 
 
In this study, four different cadherin peptides 
(HAV4, HAV6, cHAVc3, ADTC5) were evaluated in 
their effectiveness for delivering a large protein, 
galbumin, a gadolinium-labeled albumin magnetic 
resonance imaging contrast agent, into the brains of 
Balb/c mice. Both the extent and duration of BBB 
modulation by HAV6 or ADTC5 peptides was 
evaluated. Galbumin is a gadolinium-labeled albumin 
that can be detected using magnetic resonance 
imaging (MRI) due to the increase in T1 relaxation rate 
(1/T1) to produce a positive image contrast in the 




brain [21]. Due to its physicochemical properties (i.e., 
size, hydrogen binding potential, and hydrophilicity), 
galbumin cannot cross the BBB via the transcellular or 
paracellular pathways. Therefore, it is a good model 
molecule to test the activity of cadherin peptides to 
enhance brain delivery of protein via the paracellular 
pathway due to the increase in BBB paracellular 
porosity.  
Secondly, the brain delivery of 
IRdye800cw-cLABL peptide was accomplished using 
ADTC5 peptide in Balb/c mice. cLABL peptide was 
derived from the I-domain sequence of lymphocyte 
function-associated antigen-1 (LFA-1) receptors found 
on the surface of T cells. The cLABL peptide binds to 
and is internalized by intercellular adhesion 
molecule-1 (ICAM-1) on the surface of vascular 
endothelial and immune cells [22, 23]. Because 
ICAM-1 is upregulated during inflammation, the 
hypothesis is that labeled cLABL peptide can be used 
to detect changes in ICAM-1 expression in the brain 
during neuroinflammation. In this study, the brain 
deposition of cLABL was quantified using 
near-infrared fluorescence (NIRF) imaging. Although 
this peptide is smaller than galbumin, it has 
unfavorable physiochemical properties for crossing 
the BBB via the transcellular and paracellular 
pathways, thus, it is also a good model of peptide 
delivery to the brain. 
Finally, this study was carried out to evaluate the 
brain delivery of unlabeled cIBR7 peptide using 
ADTC5 peptide in Sprague-Dawley rats. The aim is to 
develop a method to extract and detect the unlabeled 
cIBR7 peptide in the brain to confirm our findings 
using labeled molecules. Sprague-Dawley rats were 
used to evaluate the applicability of ADTC5 peptide 
to enhance delivery of molecules into rat brains in vivo 
because ADTC5 has not been used in rat model 
previously. cIBR7 peptide was derived from ICAM-1 
sequence and it binds to the I-domain of LFA-1 
receptor on immune cells (i.e., T cells); therefore, brain 
delivery of cIBR7 peptide can detect the presence of 
immune cells in the brain during the 
neuroinflammation process [24-26]. Most of our 
studies to deliver molecules to the brain have been 
carried out using labeled molecules, and their brain 
deposition was detected using radioactivity, NIRF 
imaging, and magnetic resonance imaging (MRI). One 
possible caveat of using labeled molecules is that the 
labeled molecule may degrade during delivery. Thus, 
the detected quantity of the molecule may be due to a 
combination of the intact molecule and its degraded 
fragments containing the label. Therefore, unlabeled 
cIBR7 peptide was delivered using ADTC5 peptide, 
and brain depositions of cIBR7 and ADTC5 peptides 
were quantified using tandem mass spectrometry 
(LC-MS/MS).  
Materials and Methods 
Chemicals, Reagents, and Animals 
Ketamine hydrochloride and xylazine were 
purchased from MWI Veterinary Supply Co. (Boise, 
ID) and Lloyd Inc. (Shenandoah, IA), respectively. 
IRdye800cw-NHS ester was purchased from LiCOR 
Inc. (Lincoln, NE). Amino acids for peptide synthesis 
were purchased from Protein Technologies Inc. 
(Tucson, AZ). Galbumin was purchased from BioPal 
Inc. (Worcester, MA). All other reagents and 
chemicals were purchased from Sigma Aldrich 
Chemical Company (St. Louis, MO). All protocols 
involving the use of animals were approved by the 
Institutional Animal Care and Use Committee 
(IACUC) at The University of Kansas or the 
University of Manitoba. The animals were maintained 
in the Animal Care Unit with free access to food and 
water. 
Peptide Synthesis and Purification 
The synthesis of peptides (Table 1) was 
accomplished using a solid-phase peptide 
synthesizer. After peptide cleavage from the resin 
using TFA, the crude peptides were precipitated in 
cold diethyl ether. In most cases, the crude precipitate 
showed high concentration of the desired peptide. 
After purification with semi-preparative HPLC, the 
isolated peptides had high purity (>96%) as 
determined by analytical HPLC with a C18 column. 
The formation of a disulfide bond in the cyclic peptide 
(i.e., cIBR7, ADTC5, cHAVc3, IS) was accomplished by 
stirring the precursor linear peptide in bicarbonate 
buffer solution under air oxidation at pH 9.0 in high 
dilution. The cyclization reaction produced primarily 
the desired monomer with minor oligomer 
side-products; the monomer was isolated from the 
mixture using semi-preparative HPLC. Because 
cIBR7, IS, and ADTC5 peptides were quantified in the 
brain by mass spectrometry, their exact mass data are 
presented in Table 2. 
 
Table 2. Mass Spectrometry Identification of ADTC5, cIBR7 and 
IS. 




ADTC5 772.293 772.298 6.5 
cIBR7 775.315 775.316 1.3 
IS 789.331 789.336 6.3 
 
To synthesize IRdye800cw-cLABL, cLABL 
peptide (0.86 mg, 0.71 µmol, MW = 1197.2 g/mol) and 
IRdye800cw-NHS ester (5.0 mg, 4.2 µmol, MW = 




1166.2 g/mol with 3 Na+) were mixed in 1.0 mL of 0.5 
M potassium phosphate buffer at pH 8.5 followed by 
stirring overnight in the dark. The reaction progress 
was monitored by analytical HPLC with a C18 
column. After the reaction was completed, 
IRdye800cw-cLABL (MW = 2248.4 with 3 Na+ and 
2182.4 without Na+ ions) was purified using HPLC 
with a C18 semi-preparative column. The identity of 
the pure product was determined using mass 
spectrometry to give 2182.69 amu for 
IRdye800cw-cLABL without Na+ ions. 
In Vivo Delivery of Galbumin in Balb/c Mice and 
Quantification using MRI 
The effects of cadherin peptides (i.e., HAV4, 
HAV6, ADTC5, cHAVc3) to enhance brain delivery of 
65 kDa galbumin were determined in Balb/c mice. A 
Bruker Biospect MR spectrometer equipped with 7 
tesla/21 cm magnets and 2.5 × 2.5 cm2 field of view 
was used to quantify brain depositions of galbumin. 
After anesthesia, Balb/c mice were placed in the MRI 
magnet followed by simultaneous delivery of 
galbumin (0.6 μmol/kg) with the peptide (0.010 
mmol/kg). The brain was scanned with a series of T1- 
and T2-weighted images before initial delivery of 
galbumin to determine the brain background images 
and structural coordinates [17]. Every 3 minutes, 
T1-weighted images of the brain were collected for up 
to 51 min following the injection of galbumin with 
peptide. The galbumin brain deposition was 
determined using the intensity of the contrast agent 
from manually outlined regions of interest (ROI) 
within the coronal brain slices using Marevisi 3.5 
software (Institute for Biodiagnostics, National 
Research Council, Otawa, Ontario, Canada). 
Paravision 3.0 software package was used to quantify 
the increase in image intensity of galbumin in the 
brain using the following formula for percent change:  
[(Post-Gd-DTPA T1-weighted images – Pre-Gd-DTPA 
T1-weighted images) ÷ Pre-Gd-DTPA T1-weighted 
images] × 100 
In Vivo Delivery of IRdyeR800cw-cLABL into 
the Brains of Balb/c Mice and NIRF Detection  
The effect of ADTC5 in enhancing BBB 
penetration of IRdyeR800cw-cLABL in Balb/c mice 
was quantified using NIRF imaging as described 
previously [17]. Briefly, IRdye800cw-cLABL (10 
µg/mouse) along with ADTC5 (0.01 mmol/kg) was 
delivered into Balb/c mice via tail vein injection. After 
20 min, the mice were sacrificed, followed by cardiac 
perfusion with 10% formaldehyde solution [17]. The 
brains were removed and 1-mm coronal slices 
prepared for ex vivo quantitative analysis using an 
Odyssey NIRF imaging system (Licor, Lincoln, NE). 
The depositions of IRdyeR800cw-cLABL peptide in 
the brain were quantified by integrating the 
fluorescence intensities at the ROI. The integrated 
fluorescence intensities were normalized to the 
fluorescence from the blood sample at the same time 
point. The data were presented as the relative 
fluorescence units/mm3 of tissue divided by relative 
fluorescence units/μL blood. 
In vivo Delivery of cIBR7 into the Rat Brain and 
LC-MS/MS Detection 
ADTC5 peptide was used to deliver cIBR7 in 
male Sprague–Dawley rats (300–400 g). Rats were 
anaesthetized with a combination of ketamine (100 
mg/kg) and xylazine (5 mg/kg) delivered 
intraperitoneally. A heat lamp was used to maintain 
the animal’s body temperature during the 
experiment. The jugular vein of the rat was 
cannulated with a polyethylene catheter (PE 50) 
containing heparinized saline (100 IU/mL) through 
which cIBR7 (40 mg/kg) and ADTC5 (30 mg/kg) 
were administered over 10 min. Then, the rats were 
sacrificed and a heart-cut was performed followed by 
perfusion of the brain with saline to remove leftover 
peptide in the microvessels of endothelial cells of the 
BBB. The whole brain tissue was isolated and rinsed 
with saline followed by storage at –80 °C. In the 
meantime, blood was collected in tubes containing 
anticoagulants and centrifuged at 12000 rpm for 10 
min. Plasma was obtained and stored at –80 °C until 
further processing. Control studies were done 
following the same procedure but with the 
administration of only cIBR7 (without ADTC5). 
Samples were extracted and analyzed using 
LC-MS/MS. 
Capillary Depletion Method 
Parallel capillary depletion experiments were 
performed as described by Triguero et al. [27] to 
ensure that there is no trapping of the delivered 
molecules in the microvessel endothelial cells. Brain 
homogenates from rat brains dosed with cIBR7 and 
ADTC5 were mixed together and divided into two 
sets. One set of homogenates (580 μL) was extracted 
using the optimized extraction procedure (see below). 
The other set of brain homogenates was extracted 
after capillary depletion was performed to remove 
cerebral vasculature contaminants. In this method, 
580 μL of 26% dextran solution was added to 580 μL 
of brain homogenate with IS. The mixture was 
centrifuged at 5,400 g for 15 min, and the supernatant 
was extracted with 1 mL acetonitrile using the 
optimized extraction procedure described below. 




LC-MS/MS Method Development and Peptide 
Extraction and Detection Procedures 
Instrumentation and Chromatographic Conditions for 
Quantitative LCMS/MS Analysis  
The LC-MS/MS system consisted of an Acquity 
UPLC system (Waters Corp., Milford, MA) coupled to 
an electrospray (ESI) ion source and a Quattro Ultima 
triple quadrupole mass analyzer (Micromass Ltd., 
Manchester, UK). Separation was performed at room 
temperature on a Luna UPLC C18 (2.1 mm × 50 mm, 5 
μm particle size, 100 Å; Phenomenex, Inc., Torrance, 
CA) using a binary gradient mobile phase consisting 
of solvents (A) H2O:formic acid (99.92:0.08) and (B) 
acetonitrile:formic acid (99.92:0.08). The gradient was 
carried out as follows: 1% B (initial–0.5 min), 1–7% B 
(3.5 min), 7–18% B (1 min), 18–50% B (1 min), 50–80% 
B (1 min), 80% B (2 min), 80–100% B (1 min) and 100% 
B (1 min). A 20-μL sample was injected into the 
mobile phase flowing at a rate of 0.350 mL/min. Mass 
spectrometric analysis was conducted in positive ion 
mode using multiple reaction monitoring (MRM). 
Nitrogen was used as the desolvation gas and argon 
gas was used for collision-induced dissociation (CID). 
Cone voltages for the analytes and collision energies 
were set at 35–55 V and 35–120 V, respectively. MRM 
chromatograms were quantified using MassLynx v 
4.1 software (Micromass) for the integration of 
relevant peak areas. 
Preparation of Stock, Standard, and IS Solutions 
ADTC5, cIBR7, and internal standard (IS) were 
dissolved in nanopure water to prepare (1 mg/mL) 
stock solutions, which were stored at –20 °C and later 
diluted for the required working standard solutions. 
Calibrations of standard brain homogenate samples 
were prepared as follows. The working standard 
solutions (10 µL) and IS (10 µL, target concentration of 
200 ng/mL) were spiked into 580 μL of blank brain 
homogenates from untreated rats. These were 
recovered using the extraction procedure given below 
to yield a linear range from 50 to 500 ng/mL (50, 100, 
175, 250, 350, 500 ng/ml) for the calibration curves. 
Quality control (QC) samples were prepared in the 
same way. 
Sample Preparation 
Extraction of peptides from brain tissue 
The whole brain was homogenized with 0.25% 
acetic acid using a PowerGen 700 tissue homogenizer. 
590 μL aliquots of rat brain homogenate were spiked 
with 10 μL of IS (target concentration, 200 ng/mL). 
The homogenate was vortexed for 1 min followed by 
addition of 1 mL acetonitrile; the mixture was then 
vigorously vortexed again for 1 min followed by 
centrifugation at 12000 rpm. The supernatant was 
isolated, transferred to a clean tube, and evaporated to 
dryness using a Savant SpeedVac concentrator. The 
dry extract was reconstituted in 100 μL of water, 
vortexed for 30 s, and centrifuged for 10 min at 12000 
rpm to remove residual precipitated proteins.  
Extraction of peptides from plasma 
100 μL of rat plasma was spiked with 10 μL of IS 
(target concentration 200 ng/mL). The mixture was 
vortexed for 1 min followed by addition of 250 μL of 
acetonitrile. The mixture was vigorously vortexed 
again for 1 min, followed by centrifugation at 12000 
rpm. The supernatant was isolated, transferred to a 
clean tube, and evaporated to dryness using a Savant 
SpeedVac concentrator. The dry extract was 
reconstituted in 100 μL of water, vortexed for 30 s, and 
centrifuged for 10 min at 12000 rpm to remove 
residual precipitated proteins. 
Extraction Recovery 
Recovery and matrix effects of cIBR7 and 
ADTC5 were tested in the spiked rat brain 
homogenates at three concentrations 50, 250 and 500 
ng/mL. Extraction recovery of cIBR7 and ADTC5 
from brain tissue homogenate was determined by the 
ratios of peak areas in the post-extraction spiked 
samples and in pre-extraction spiked samples.  
Accuracy, Precision, and Stability 
The intra-day as well as inter-day accuracy and 
precision were calculated by analyzing replicates of 
spiked brain homogenates at three concentrations 50, 
250 and 500 ng/mL. The stability of the cIBR7 and 
ADTC5 peptides in spiked brain homogenates was 
evaluated under different temperature and storage 
conditions. Three sets of samples were subjected to (a) 
room temperature for 10 h, (b) −20 °C for 24 h 
followed by unassisted thawing at room temperature, 
and (c) three freeze-thaw cycles between −20 °C and 
room temperature over a 24-h period. The total 
chromatogram time for one sample was 11 min, and 
the total duration for a set of samples for the 
experiment per day was less than 8 h. All stability 
studies were conducted using 50, 250, and 500 ng/mL 
of cIBR7 and ADTC5 with three determinations for 
each concentration of peptide. 
Statistical Analysis 
For brain delivery of peptides and galbumin, the 
differences in the brains treated with or without BBB 
modulators were compared using ANOVA with 
Student–Newman–Keuls for determining the 
statistical significance. A p-value of less than 0.05 was 
used as a criterion for statistical significance. 





In Vivo Brain Delivery of Galbumin in Balb/c 
Mice as Detected by MRI 
The activity of cadherin peptides (i.e., HAV6, 
HAV4, cHAVc3, and ADTC5) to enhance the brain 
delivery of galbumin into the brain of Balb/c mice 
was evaluated. The HAV6, cHAVc3, and ADTC5 
treatment groups showed a significant increase in the 
brain deposition of galbumin in the posterior, 
midbrain, anterior regions compared to those of 
vehicle (Figures 1A–D). The enhanced brain delivery 
of galbumin was observed as early as 3 min after the 
i.v. injection (Figures 1B–D). In contrast, the HAV4 
treatment group did not show an enhancement of 
galbumin brain deposition. From the AUC (Figure 
1D), the levels galbumin enhancement were in the 
following order: posterior > midbrain > anterior. 
To evaluate the duration of BBB opening for 
large macromolecules, galbumin was delivered 10 or 
40 min after administration of HAV6 and ADTC5 
peptides in a pretreatment experiment. 
Time-dependent galbumin brain depositions are 
shown in Figures 2A–D for 10-min pretreatment and 
in Figures 2A and 2E–G for 40-min pretreatment. The 
galbumin AUCs were also shown on immediate as 
well as 10- and 40-min pretreatment experiments 
(Figure 3). As previously shown, immediate delivery 
of galbumin with the HAV6 or ADTC5 peptide 
produced significant enhancements of galbumin brain 
deposition in all brain regions. After 10-min 
pretreatment with ADTC5, that there was still 
significant enhancement of brain deposition of 
galbumin while no enhancement was observed with 
HAV6 pretreatment. Using 40-min pretreatment, 
there was no observed galbumin enhancement 
produced by ADTC5 or HAV6. 
In Vivo Brain Delivery of R800cw-cLABL in 
Balb/c Mice as Detected by NIRF Imaging 
The brain delivery of a 12-amino acid peptide, 
IRdye800cw-cLABL (MW = 2182.4 g/mol), was 
accomplished via i.v. administration in the presence 
and absence of ADTC5 (Figure 4). Twenty minutes 
after i.v. administration, the mice were sacrificed. 
NIRF imaging was used to detect peptide brain 
deposition. The labeled cLABL peptide delivered with 
ADTC5 has qualitatively higher brain fluorescence 
than that without ADTC5 (Figures 4A–B). 
Quantitatively, the brain-to-plasma ratio was used to 
determine the effect of ADTC5; the brain deposition of 
cLABL with ADTC5 was about 3.5-fold higher than 
that without ADTC5 (Figure 4C, bottom panel). 
LC-MS/MS Method Development for 
Quantification of cIBR7 in Rat Brain 
For calculating the amounts of peptides in the rat 
brains, liquid chromatography and tandem mass 
spectroscopy conditions were optimized to achieve 
the best separation and quantification of cIBR7, 
ADTC5, and the IS peptides in the rat brain extracts. 
The standard solution for each peptide was infused 
into the mobile phase using a syringe; the dominant 
peaks were observed with mass-to-charge ratios of 
m/z 776.5, 773.5, and 395.9 for cIBR7, ADTC5, and IS, 
respectively. MRM was used for each precursor ion to 
produce three respective transitions, including m/z 
776.5 Æ m/z 70.2 for cIBR7; m/z 773.5 Æ m/z 294.1 
for ADTC5 and m/z 395.9 Æ m/z 86 for IS using 
optimized collision energies of 120 V, 35 V, and 35 V, 
respectively. 
Validation of Mass Spectrometric Method 
Selectivity 
Selectivity of the method was evaluated by 
analyzing chromatograms of blank brain homogenate 
samples and blank brain homogenates spiked with 
cIBR7, ADTC5, and IS. The results showed no 
endogenous interferences at the retention times of the 
three analytes (Figure 5). The retention times for 
cIBR7, IS, and ADTC5 were 2.88 min, 3.80 min, and 
6.10 min, respectively. 
Linearity, Accuracy, and Precision 
 Calibration curves for cIBR7 and ADTC5 were 
prepared in concentrations ranging from 50 to 500 
ng/mL to determine the lowest limit of detection 
(LLOD) and intra-day and inter-day accuracy and 
precision (Table 3). In this case, the peak area ratios of 
cIBR7-to-IS and ADTC5-to-IS were plotted separately. 
Good linearity was observed for both cIBR7 and 
ADTC5 with R2 ≥ 0.99. The LLOD for cIBR7 and 
ADTC5 were 15 ng/mL and 10 ng/mL, respectively. 
Intra-day and inter-day accuracy and precision were 
determined by analyzing samples at three 
concentration levels for %RSD and %RE (Table 3). The 
%RSD and %RE values were less than 15% for 
intra-day and inter-day for both analytes.  
 




%RSD %RE %RSD %RE 
cIBR7 50 10.1 14.1 9.6 11.2 
 250 9.9 4.1 9.1 –1.9 
 500 8.5 2.3 6.4 3.3 
ADTC5 50 7.4 6.6 12.4 3.7 
 250 14.6 –3.3 6.7 2.1 
 500 10.5 2.5 7.1 4.2 
 





Figure 1. The effects of cadherin peptides (HAV6, HAV4, ADTC5, and cHAVc3) on enhancing brain delivery of 65 kDa galbumin as monitored MRI. (A) T1-weighted 
MR images of brain depositions of galbumin at 0 and 9 min time points when delivered with and without peptide. The depositions of galbumin were observed in the 
posterior, midbrain, and anterior regions as gray spots (see red arrows). (B–D) The time-dependent brain depositions of galbumin in the (B) posterior, (C) midbrain, 
and (D) anterior regions as monitored by MRI every 3 min over a 51-min imaging session. (E) The AUC of galbumin brain depositions when delivered with peptides 
or control vehicle. Star (*) represents statistical significant with p < 0.05 as evaluated using ANOVA with Student–Newman–Keuls post hoc comparison of the means 
(n = 3).  














   
Figure 2. Comparison of 10-min and 40-min pretreatment with HAV6 or ADTC5 peptide on the brain depositions of galbumin. (A) T1-weighted MR image 
comparisons of brain depositions of galbumin after 10-min and 40-min pretreatment with HAV6 and ADTC5. The brain depositions of galbumin were observed as 
gray spots (see red arrows) in the posterior, midbrain, and anterior regions at 0 and 9 min time points using MRI. (B–D) Time-dependent brain depositions of 
galbumin observed at the (B) posterior, (C) midbrain, and (D) anterior regions when delivered 10 min after HAV6 or ADTC5 administration. (E–G) 
Time-dependent brain depositions of galbumin observed at the (E) posterior, (F) midbrain, and (G) anterior regions when delivered 40 min after HAV6 or ADTC5 
administration. Star (*) represents statistical significance with p < 0.05 as evaluated using ANOVA with Student–Newman–Keuls post hoc comparison of the means 
(n = 3). 
 
 
Figure 3. Comparisons of the AUC of galbumin brain deposition upon (A) immediate, (B) 10-min, and (C) 40-min pretreatment with HAV6 and ADTC5 peptides. 
(A) Immediate delivery with HAV6 or ADTC5 peptide significantly enhanced brain deposition of galbumin in posterior, midbrain, and anterior regions. (B) With 
10-min pretreatment, ADTC5 still significantly enhanced the delivery of galbumin while HAV6 did not. (C) With 40-min pretreatment, there was no enhancement in 
galbumin accumulation in the brain with either ADTC5 or HAV6 peptide. Star (*) represents statistical significant with p < 0.05 as evaluated using ANOVA with 
Student–Newman–Keuls post hoc comparison of the means (n = 3). 





Figure 4. The effect of ADTC5 peptide on increasing the brain deposition of IRdye800cw-cLABL peptide after i.v. administration in Balb/c mice as detected by NIRF 
imaging. (A) The images of brain depositions of IRdye800cw-cLABL in different slices of the brain from anterior to posterior regions when delivered with vehicle (left) 
and ADTC5 (right). (B) The additive representation of brain depositions of IRdye800cw-cLABL when delivered with vehicle (left) or ADTC5 (right). (C) Comparison 
of brain-to-plasma ratios of IRdye800cw-cLABL peptide when administered with vehicle (control) and ADTC5. Star (*) indicates statistical significance with p < 0.05; 
ADTC5-treated group, n = 4; control group, n =3. The error bars represent SD. 
 
 
Figure 5. MRM chromatograms of brain extracts with (A) cIBR7 peptide (left) 
and blank (right), (B) IS peptide (left) and blank (right), and (C) ADTC5 peptide 
(left) and blank (right). The peptide separation was done using a Luna UPLC C18 
column with 2.1 mm × 50 mm dimensions, particle size 5 μm, and pore size 100 
Å (Phenomenex, Inc., Torrance, CA). The elution was done using a binary 
gradient mobile phase consisting of solvent A: H2O:formic acid (99.92:0.08) and 
solvent B: acetonitrile:formic acid (99.92:0.08). 
Stability and Extraction Recovery 
The potential instability of cIBR7 and ADTC5 
during the experiments was determined in three 
different peptide concentrations, temperatures, and 
storage conditions (Table 4). The variability of each 
peptide in the brain extract was calculated to be less 
than 15% (%RSD) (Table 4). The extraction recoveries 
of cIBR7 and ADTC5 from the brain homogenates 
were calculated by comparing the extracted and 
spiked samples. At three concentrations, the 
calculated mean recoveries for cIBR7 and ADTC5 
were 90% and 92%, respectively (Table 5).  
 






–20 °C Three freeze 
thaw cycles 
cIBR7 50 7.79 13.54 9.72 
 250 9.48 1.90 5.72 
 500 8.73 8.96 6.34 
ADTC5 50 12.18 9.18 13.12 
 250 10.61 0.45 11.01 
 500 6.95 7.16 8.97 
 
In Vivo Brain Delivery of cIBR7 in 
Sprague-Dawley Rats 
The brain delivery of cIBR7 was evaluated in 
Sprague-Dawley rats following bolus i.v. injection of 




cIBR7 either alone or in combination with the 
cadherin peptide ADTC5. The amount of cIBR7 in the 
brain in the presence of ADTC5 was significantly 
higher (approximately four times) than that without 
ADTC5 (p = 0.013, Figure 6). In the presence of 
ADTC5, the average total amount of cIBR7 was 855 ± 
171 ng/g brain while it was 213 ± 53 ng/g brain in the 
absence of ADTC5. Brain accumulation of cIBR7 was 
also determined in brain homogenates following 
capillary depletion to remove any cIBR7 within the 
brain vasculature. In this case, the ratios of cIBR7-to-IS 
without and with vasculature depletion were 0.133 
and 0.128, respectively. This suggests that there is no 
difference between the two methods.  
 
Table 5. Extraction recovery of cIBR7 and ADTC5 from rat brain 
homogenate 
Analytes Concentration (ng/mL) Extraction Recovery (%) 
cIBR7 50 89 
 250 90 
 500 92 
ADTC5 50 90 
 250 92 





Figure 6. The effect of ADTC5 peptide on enhancing brain delivery of cIBR7 
peptide in rats as detected by LC-MS/MS. cIBR7 (40 mg/kg) was delivered in the 
presence or absence of ADTC5 (30 mg/kg). The rats were sacrificed after 10 
minutes, and the whole brains were collected for analysis. The total amount of 
cIBR7 in rat brains after in vivo delivery via i.v. administration was significantly 
higher in the presence of ADTC5 compared to control with PBS treatment. Star 
(*) indicates a significant difference from the control study with p < 0.05. Error 
bars show the mean ± SE from ADTC5-treated group (n = 5) and PBS-treated 
group (n = 4). 
 
Discussion 
The delivery of peptides and proteins including 
antibodies (MW~150 kDa) or Fab-fragment of 
antibodies (MW~50 kDa) into the brain for diagnosis 
and treatment of brain diseases had been a topic of 
great interest. However, success in delivering them to 
the brain has been very limited because they have 
physicochemical properties (e.g., size, 
hydrogen-bonding potential, and conformation) that 
prevent them from partitioning into cell membranes 
to cross the BBB [1]. There is clearly a need to develop 
methods to deliver peptides and proteins into the 
brain. The ability to deliver functional peptides and 
proteins, including antibodies, into the brains of 
normal and diseased animals (i.e., mice and rats) 
would provide advantages in treating various brain 
pathologies and studying brain functions at the 
cellular level. Previously, cadherin peptides have 
been shown to improve in vivo delivery of 
small-to-large marker molecules, including 25 kDa 
IRdye-800cw PEG, into the brains of mice and/or rats 
[16-18, 20]. In in vivo Balb/c mice, HAV6 peptide also 
enhances the delivery of IRdye-800cw PEG in the 
lung, kidney, and small intestine [17]. It should be 
noted that the PEG molecule has physicochemical 
properties different from those of peptides and 
proteins in that they have a variety of functional 
groups as well as secondary or tertiary structures. 
The first aim was to determine brain delivery of 
a large protein, 65 kDa galbumin, using several 
known cadherin peptides (i.e., HAV6, HAV4, 
cHAVc3, or ADTC5) in Balb/c mice. Galbumin is a 
conjugate between albumin and Gd-complex; thus, it 
can be detected and quantified in the brains of living 
animals using MRI. Compared to vehicle control, 
ADTC5, HAV6, and cHAVc3 peptides significantly 
enhanced the delivery of galbumin into all three 
regions of the brain (i.e., posterior, midbrain, and 
anterior). The enhancement was immediate— within 
3 min after administration of the modulator peptide 
with galbumin (Figure 1B–D). Our hypothesis is that 
cadherin peptides open the intercellular junctions to 
create small, medium, and large pores in the 
paracellular pathways of the BBB as soon as the 
peptide is injected [18]. It is interesting to find that 
HAV4 did not enhance galbumin brain delivery 
(Figure 1D); however, HAV4 did enhance brain 
delivery of Gd-DTPA [20]. This suggests that HAV4 
creates small pores but is unable to create the large 
pores in the intercellular junctions of the BBB required 
for delivery of macromolecules to the brain. Overall, 
ADTC5, HAV6, and cHAVc3 can effectively enhance 
the brain delivery of a protein as large as 65 kDa in 
Balb/c mice. 
The duration of the BBB opening created by 
HAV6 and ADTC5 peptides to allow large molecules 
to enter the brain is an important parameter for 
avoiding unwanted side effects of this method. The 
opening of BBB paracellular pathways for brain 
delivery should be tightly controlled to avoid BBB 
permeation of unwanted large molecules and 
immune cells (e.g., macrophages, T cells, and B cells) 
entering the brain. Therefore, the time-dependent 




effect of pretreatment using HAV6 or ADTC5 on the 
BBB permeation of galbumin was investigated. As 
expected, immediate treatment with HAV6 or ADTC5 
peptide along with galbumin showed enhanced brain 
deposition of galbumin (Figure 3A). In contrast, 
ADTC5 but not HAV6 enhanced the brain delivery of 
galbumin when a 10-min peptide pretreatment 
experiment was conducted (Figure 3B). This indicates 
that the duration of the BBB opening provided by 
HAV6 peptide for a large molecule is less than 10 min 
and shorter than that produced by ADTC5. In 
contrast, the BBB opening for a large molecule by 
ADTC5 lasts longer than 10 min. After 40-min 
pretreatment, there was no enhancement of galbumin 
deposition in the brain by either peptide. This 
suggests that the duration of BBB opening for ADTC5 
was longer than 10 min but shorter than 40 min. 
Overall, for both HAV6 and ADTC5, the BBB opening 
for large molecular weight molecules was reversible 
and short. 
In previous studies, HAV6, HAV4, cHAVc3, and 
ADTC5 peptides significantly enhanced the brain 
delivery of a small molecular weight vasculature 
marker, Gd-DTPA (MW = 547.575 g/mol), in a 
dose-dependent manner [17, 18, 20]. To determine the 
duration of BBB opening created by cadherin peptides 
for a small molecule, pretreatment studies were 
carried out using Gd-DTPA and detected by MRI. 
Following a 1-h pretreatment with peptide, linear 
HAV6 and HAV4 peptides did not aid the penetration 
of Gd-DTPA through the BBB, suggesting that the 
BBB opening created by these linear peptides lasts less 
than 1 h. In contrast, cyclic ADTC5 and cHAVc3 
peptides create a BBB opening for Gd-DTPA delivery 
of more than 2 h but less than 4 h [18, 20]. Therefore, 
cyclic ADTC5 and cHAVc3 peptides created a longer 
lasting BBB opening than did linear HAV6 and HAV4 
peptides. The data suggest that both HAV6 and 
ADTC5 peptides create a longer duration of BBB 
opening for a small molecule (i.e., Gd-DTPA) than a 
large molecule (i.e., galbumin). To explain the 
observations in the pretreatment studies, it is 
proposed that cadherin peptides modulate the BBB by 
immediately creating small, medium, and large pores 
in the intercellular junctions. However, the large 
pores quickly collapse to medium and small pores 
and, finally, the medium pores collapse to small pores 
in the intercellular junctions of the BBB. 
To evaluate brain delivery of peptides, a 
12-amino acid residue peptide, IRdye800cw-cLABL 
peptide, was delivered with ADTC5 in Balb/c mice. 
The peptide brain deposition was detected using 
NIRF imaging, which has an advantage in its ease of 
quantifying the molecule. The administration of 
ADTC5 peptide significantly enhanced brain delivery 
of cLABL peptide compared to control. The data 
suggest that the mechanism of transport of cLABL 
peptide was via passive diffusion through the 
paracellular pathway of the BBB. Although cLABL 
peptide could bind to and be internalized by ICAM-1 
on the surface of BBB endothelial microvessels, the 
brain deposition of this peptide when delivered with 
vehicle was very low, suggesting that ICAM-1 
receptor-mediated endocytosis was not involved 
(Figure 4). cLABL peptide was selected because it 
binds to ICAM-1 protein on the surface of epithelial, 
endothelial, and immune cells. ICAM-1 is 
upregulated during inflammation [22, 23]; thus, it can 
be used as a target protein for labeled cLABL to detect 
upregulation of ICAM-1 during neuroinflammation. 
cLABL peptide is derived from the binding region of 
the I-domain of LFA-1 to the domain-1 (D1) of 
ICAM-1 [28]. It binds to ICAM-1 and inhibits 
LFA-1/ICAM-1-mediated T-cell adhesion to epithelial 
cells [29]. In addition, it is also internalized by 
ICAM-1 in activated Molt-3 T cells [23].  
The final aim is to develop a method to detect 
and quantify an intact peptide in the brain without the 
use of any radioactive, MRI, or NIRF label. cIBR7 
peptide was selected for brain delivery using ADTC5 
peptide in Sprague-Dawley rats; ADTC5 has not been 
evaluated in modulating the BBB of in rats in vivo. 
Previously, ADTC5 peptide was shown to enhance 
brain delivery of 14C-mannitol in an in situ rat brain 
perfusion model [18]. In addition, HAV6 peptide has 
been shown to enhance brain delivery of an MRI 
contrast agent, Gd-DTPA, in in situ brain perfusion 
and in vivo in Sprague-Dawley rats [16]. These results 
suggest that ADTC5 could also enhance the brain 
delivery of cIBR in rats. To detect the brain deposition 
of cIBR7, an extraction as well as a sensitive and 
selective LC-MS/MS method were developed to 
detect and quantify the delivered peptide in the rat 
brain. cIBR7 peptide was delivered in the presence of 
ADTC5 or control by injection via the jugular vein. 
After 10 min, the rat was sacrificed and the BBB was 
perfused with saline to remove potential residual 
peptides in the vascular endothelial cells to ensure 
accurate measurement of the analyte concentration in 
the brain. ADTC5 significantly enhanced the brain 
delivery of unlabeled cIBR7 peptide by as much as 
4-fold (Figure 6, p = 0.013), and 855 ± 171 or 213 ± 53 
ng/g brain of cIBR7 was detected when delivered 
using ADTC5 or vehicle, respectively. In summary, 
this study showed that ADTC5 enhanced the brain 
delivery of intact cIBR7 in Sprague-Dawley rats, and 
that the extraction and LC-MS/MS detection methods 
were sensitive to quantified cIBR7 brain deposition. 
 cIBR7 peptide was selected because it binds to 
LFA-1 receptors on the surface of T cells and inhibits 




T-cell adhesion to Caco-2 cell monolayers [25]. cIBR7 
is a smaller analog of the parent cIBR peptide, which 
is derived from the D1 of ICAM-1. cIBR peptide has 
been shown to bind to the I-domain of LFA-1 receptor 
[25, 26, 30]. cIBR7 and cIBR peptides can be 
internalized by LFA-1 into the cytoplasmic domain of 
immune cells (i.e., T cells, H-60 leukemic cells) [24, 31]; 
therefore, labeled cIBR and cIBR7 peptides have the 
potential to detect LFA-1-expressing immune cells in 
the brain.  
It is interesting to find that the ADTC5 peptide 
was also detected in a lower amount (about 23 ng/g 
brain) than cIBR7 (855 ng/g brain) in the brain 
although they were administered at almost similar 
dosage levels (i.e., 40 mg/kg cIBR7 and 30 mg/kg 
ADTC5). There are several potential reasons for this 
difference. First, ADTC5 could bind to cadherins in 
the adherens junctions of the BBB to lower the amount 
of free ADTC5 that would be available to penetrate 
the BBB. The half-lives (t1/2) of plasma stabilities of 
ADTC5 and cIBR7 were 5.7 h and 2.8 h, respectively, 
suggesting that the low amount of ADTC5 in the brain 
was not due to its instability in plasma. Another 
alternative explanation is that cIBR7 and ADTC5 have 
vastly different pharmacokinetic and 
pharmacodynamic profiles; thus, further studies are 
needed to understand the difference in their brain 
depositions. 
This study developed and validated an 
extraction as well as a sensitive LC-MS/MS method to 
quantify the intact cIBR7, ADTC5, and IS in rat brains 
after in vivo studies. The results showed that cIBR7 
peptide could be detected confidently as an intact 
molecule in the brain. The optimized extraction was 
very efficient, and it recovered higher than 90% of the 
intact cIBR7 and ADTC5 peptides from the brain 
(Table 5). The recoveries of cIBR7 and ADTC5 
peptides from the brain were accomplished by 
optimizing the homogenization medium, composition 
of extraction solvent, and the reconstitution solvent 
mixture. In addition, this study also confirmed our 
previous observation on brain delivery of labeled 
molecules (i.e., radioactive, IRdye, and Gd-DTPA). It 
also suggests that the detected labeled molecules 
could reasonably represent the intact molecules in the 
brain and are not due to detection of the label or 
molecular fragments of the parent molecules. 
IS peptide was designed as a reference molecule 
for the LC-MS/MS analysis to maximize the precision 
of peptide quantification in the brain and it has 
similar physicochemical properties as cIBR7 peptide. 
It was also used to account for errors and losses 
during sample handling and ionization during 
LC-MS/MS experiments. IS peptide was designed to 
have physicochemical properties similar to those of 
cIBR7 peptide. In this case, the Val6 residue in cIBR7 
peptide was replaced with the Ile6 residue, and this 
simple change in IS provided a longer retention time 
(3.8 min) for IS compared to cIBR7 peptide (2.88 min) 
in the C18 column of LC-MS/MS (Figure 5). The 
ADTC5 peptide was eluted at 6.10 min, which is 3.8 
min later than IS peptide; therefore, all three peptides 
were well separated in the column. All three peptides 
(cIBR7, IS, ADTC5) were readily water soluble and, 
thus, no other additives or co-solvents were need for 
peptide reconstitution during the study. 
To improve the sensitivity of analyte detection, 
mass spectrometry (MS) parameters were initially 
optimized using a direct infusion of each analyte to 
the instrument, and the MRM of several stable 
transitions were optimized for each analyte. The best 
transition with the highest intensity was selected for 
each analyte. Then, the method validations for QC 
samples were carried out to determine selectivity, 
linearity, accuracy, precision, sensitivity, and stability 
over a range of concentrations in the calibration curve 
at 50–500 ng/mL following FDA guidelines [32]. The 
results showed that the LC-MS/MS method was 
selective for all three analytes with no interferences. A 
good linearity was achieved over a concentration 
range of 50–500 ng/mL for cIBR7 and ADTC5. 
Intra-day and inter-day precision and accuracy 
variability for both cIBR7 and ADTC5 were less than 
15% (R.S.D and R.E) (Table 3), suggesting that the MS 
method is accurate and precise. Variability (%R.S.D) 
for stability for both peptides was less than 15%, 
suggesting that the analytes are stable in brain extract 
under different conditions. Thus, the developed 
LC-MS/MS method was very sensitive and reliable 
for detecting the amount of delivered peptides in the 
brain. 
The hypothesis for the mechanism of action of 
cadherin peptides is that they bind in equilibrium 
fashion to the extracellular domain of E-cadherins to 
inhibit E-cadherin homophilic physical interactions 
(i.e., trans and/or cis interactions) among cadherins in 
the intercellular junctions in an equilibrium fashion 
[33]. The physical nature of this inhibition is not 
expected to change the expression of E-cadherin on 
the cell surface. Incubation of MDCK cell monolayers 
(2–4 h) with HAV6 peptide increased the total 
expression of E-cadherin in response to peptide 
modulation of the intercellular junction [14]. 
However, it is still not clear whether the same 
phenomenon occurs in the BBB. Although E-cadherin 
is found on the epithelial cells and VE-cadherin 
(cadherin-5) is found in the peripheral vascular 
endothelium [34], we found that proteins from bovine 
brain microvessel endothelial cells (BBMEC) react 
only with anti-E-cadherin antibody and not with 




anti-cadherin-5 and anti-N-cadherin [35]. Abbruscato 
and Davis indicated that BBMEC monolayers also 
expressed E-cadherin [36]. Vorbrodt et al. showed 
VE-cadherin in the rat endothelial BBB and a weak 
reaction with anti-E-cadherin [37]; however, Vorbort 
et al. [38] and Rubin et al. [34] suggested that 
VE-cadherin might not be associated with BBB 
function. Fluorescence-labeled HAV decapeptide and 
anti-E-cadherin mAb can bind to the intercellular 
juctions of the BBMEC monolayers as punctate 
structures as observed by fluorescence microscopy 
[35]. This labeled HAV peptide can also bind to single 
cells of BBMEC as detected by flow cytometry [35]. 
HAV peptides and anti-E-cadherin mAb also inhibit 
cadherin-mediated homotypic single cell aggregation 
of BBMEC [39]. Taken together, these results suggest 
that there is a potential role of E-cadherin in the BBB. 
At this point, it is not clear whether these peptides 
also bind to VE-cadherin. 
To test whether cadherin peptides can bind to 
E-cadherin, the 15N-labeled extracellular-1 (EC1) 
domain of E-cadherin was expressed and was titrated 
with cadherin peptides (i.e., ADTC5, HAV6, and 
cHAVc3). These cadherin peptides caused changes in 
chemical shifts of several amino acids on the EC1 as 
observed using heteronuclear single quantum 
correlation (HSQC) NMR spectroscopy experiments 
[33]. A combination of NMR spectroscopy and 
molecular docking experiments indicated that HAV6 
and cHAVc3 peptides have a different binding site 
than that of ADTC5 peptide. The binding site of 
HAV6 and cHAVc3 is at residues Y36, I38, F77, S78, 
and I94 on the EC1 domain [33]; in contrast, ADTC5 
binds to residues I4, P5, P6, S8, and P10 on the 
N-terminal β sheet of the EC1 domain. To put these 
results into perspective, the X-ray structure of 
C-cadherin was used to explain the potential 
mechanism of action of HAV- or ADT-peptides. 
C-cadherin could form cis- and trans-interactions. The 
cis-interactions are formed via the EC1 domain of one 
molecule to the EC2 domain of a neighboring 
molecule on the same cell membranes [40]. In 
contrast, the trans-interactions are formed by domain 
swapping of two N-termini of one EC1 domain from 
two opposing cell membranes. In the trans-interaction, 
the Trp residue at the N-terminus of one EC1 binds to 
a hydrophobic binding pocket of another EC1 domain 
from the opposing cell [40]. Using a combination of 
the X-ray structure of C-cadherin and our NMR 
binding and molecular docking studies, we 
hypothesize that HAV peptides block the EC1-EC2 
cis-interactions of two cadherins from the same cell 
membranes to create greater porosity of the 
intercellular junctions of the BBB [33]. In contrast, 
ADTC5 binds to the domain-swapping region of two 
EC1 domains for trans-interactions of E-cadherin from 
the opposing cell membranes. In summary, the results 
suggest that HAV6 peptide disrupts the intercellular 
junctions of the BBB via inhibition of cis-cadherin 
interactions while ADTC5 modulates the BBB 
opening by inhibiting the trans-cadherin interactions.  
Conclusion 
This study has shown that cadherin peptides 
enhance the delivery of functional molecules such as a 
65 kDa galbumin and peptides (i.e., cIBR7, cLABL). 
Both ADTC5 and HAV6 peptides create a short 
opening of the BBB for delivering a large molecule 
(i.e., galbumin) compared to a small molecule (e.g., 
Gd-DTPA). The intact cIBR7 peptide can be efficiently 
detected and quantified in the brain using 
LC-MS/MS. ADTC5 has been shown to modulate the 
BBB and enhance the brain delivery of molecules in 
mouse and rat models. The results suggest that there 
is compatibility of quantifying molecules in the brain 
using MRI, NIRF, and LC-MS/MS. Finally, BBB 
modulation by cadherin peptides depends on (a) the 
type and dose of modulator peptide, (b) the timing of 
delivery between BBB modulator and the delivered 
molecule, and (c) the size of the delivered molecules. 
These results further support potential uses of 
cadherin peptides in delivering molecules to the 
brains of animal models of brain diseases for 
treatment, diagnosis, and evaluation of mechanisms 
of progression of brain diseases. 
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